| Trial ID: | L3744 |
| Source ID: | NCT05769868
|
| Associated Drug: |
Esmolol Injection [Brevibloc]
|
| Title: |
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
|
| Acronym: |
CIBERbBECHO
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Cirrhosis|Diabetes Mellitus|Oncologic Disorders
|
| Interventions: |
DRUG: Esmolol Injection [Brevibloc]
|
| Outcome Measures: |
Primary: Left Ventricle (LV) ejection fraction, Estimated with 3D echocardiography (Both: convectional and with esmolol administration), At Baseline (Day 1) until Month-24 according to cohort|Peak measurement of global LV systolic longitudinal strain, Estimated with 3D echocardiography (Both: convectional and with esmolol administration), At Baseline (Day 1) until Month-24 according to cohort|Ejection Intraventricular Pressure Difference (EIVPD) measure, Estimated with M-mode echocardiography (Both: convectional and with esmolol administration), At Baseline (Day 1) until Month-24 according to cohort | Secondary: Ejection fraction, Obtained with 2D echocardiography (Simpson's biplane method), At Baseline (Day 1) until Month-24 according to cohort|Interleukin (IL)-1β, Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|High-sensitivity IL-6 (hsIL-6), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|Soluble Suppression of Tumorigenicity 2 (ST-2), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|N-terminal fragment of brain natriuretic peptide (NT-proBNP), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|Ultrasensitive troponin I (hsTnI), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|Procollagen type I terminal propeptide (PICP), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|C-terminal telopeptide collagen type I (CITP), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort|Matrix metalloproteinase-1 (MMP-1), Biochemical variables in blood in relation to the alteration of the different components of the myocardium, At Baseline (Day 1) until Month-24 according to cohort
|
| Sponsor/Collaborators: |
Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER) | Collaborators: Instituto de Salud Carlos III
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
1000
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2023-04-18
|
| Completion Date: |
2027-09
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-01
|
| Locations: |
Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitari i Politècnic La Fe, Valencia, 46026, Spain
|
| URL: |
https://clinicaltrials.gov/show/NCT05769868
|
